Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/II Dose Escalation Trial to Assess Safety of Intrathecal Trastuzumab for the Treatment of Leptomeningeal Metastases in HER2 Positive Breast Cancer

NCT01325207 is registered in ClinicalTrials.gov with Northwestern University as lead sponsor.

NCT NCT01325207
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01325207 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/II Dose Escalation Trial to Assess Safety of Intrathecal Trastuzumab for the Treatment of Leptomeningeal Metastases in HER2 Positive Breast Cancer
Lead sponsor
Northwestern University
Phase
Phase 1/2
Overall status
Completed
Start date
August 1, 2011
Completion date
January 20, 2019
Enrollment
34 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer